Download PDF
Thromb Haemost 1997; 77(02): 317-322
DOI: 10.1055/s-0038-1655961
Original Article
Schattauer GmbH Stuttgart

Production Method Affects the Pharmacokinetic and Ex Vivo Biological Properties of Low Molecular Weight Heparins

David Brieger
1   Applied Research Group, The Heart Research Institute, Sydney, Australia
,
Joan Dawes
1   Applied Research Group, The Heart Research Institute, Sydney, Australia
2   CRC for Biopharmaceutical Research, Darlinghurst, NSW, Australia
› Author Affiliations
Further Information

Publication History

Received 25 March 1996

Accepted after revision 10 September 1996

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Low molecular weight (LMW) heparins have prolonged circulating half-lives relative to unfractionated heparin, but the rates of plasma clearance differ between different LMW preparations. To determine the impact of method of production on their pharmacokinetic and ex vivo biological properties, two LMW heparins of similar molecular weight distribution, Logiparin and Fragmin, were radiolabelled with 125I, administered intravenously with 4 mg/kg of carrier drug into rabbits, and the circulating radiolabelled material and anti-Xa activity were analysed by size exclusion chromatography and affinity for antithrom#bin and Polybrene. Following administration of Logiparin, the anti-Xa amidolytic activity was eliminated with the same half-life as the anti#thrombin-binding radiolabel and was not neutralised by antibody against tissue factor pathway inhibitor (TFPI). Larger molecules were cleared preferentially and were no longer detectable 8 h post injection. These findings resemble those we have previously described for Enoxaparin. After Fragmin administration the antithrombin binding radiolabel was cleared more rapidly than the anti-Xa activity, and at late times after injection a significant amount of this activity was neutralised by antibody against TFPI. Sulphated radiolabel was eliminated with a similar half-life to the anti-Xa activity and sulphated molecules >6000 Da remained in the circulation 8 h after administra#tion. Fragmin, unlike Logiparin and Enoxaparin, has no negatively charged sulphamino group at the reducing end of the molecule. We sug#gest that this minimises cellular interaction and protects the larger molecules from elimination. They remain in the circulation, contributing to anti-Xa activity by binding TFPI. Thus the method of production of LMW heparins may significantly influence their pharmacokinetic properties and circulating anticoagulant activities.

 

  • References

  • 1 Dawes J, Pepper D. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedSearch in Google Scholar
  • 2 Boneu B, Caranobe C, Sié P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-291
    CrossrefPubMedSearch in Google Scholar
  • 3 Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley and Sons; Chichester, New York, Brisbane, Toronto, Singapore: 1992
    Search in Google Scholar
  • 4 Doutrempuich C, Guyot M, Lalanne M, Deharo E, Walenga J, Fareed J. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. Thromb Res 1989; 55: 419-426
    CrossrefPubMedSearch in Google Scholar
  • 5 Brieger D, Dawes J. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Thromb Haemost 1994; 72: 275-280
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Lam L, Silbert J, Rosenberg R. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-577
    CrossrefPubMedSearch in Google Scholar
  • 7 Dawes J, Prowse C, Pepper D. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma serum and urine. Thromb Haemost 1985; 54: 630-634
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Greenwood F, Hunter W, Glover J. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123
    PubMedSearch in Google Scholar
  • 9 Andersson L, Barrowcliffe T, Holmer E, Johnson E, Sims G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 09: 575-583
    CrossrefPubMedSearch in Google Scholar
  • 10 Hodson B, Pepper D, Dawes J. Novel affinity chromatographic system for the single step purification of glycosaminoglycans from complex systems using volatile buffers. J Chromatog 1991; 565: 416-423
    CrossrefPubMedSearch in Google Scholar
  • 11 Teien A, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
    CrossrefPubMedSearch in Google Scholar
  • 12 Fareed J, Walenga J, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556: 333-353
    CrossrefPubMedSearch in Google Scholar
  • 13 Østergaard P, Nilsson B, Bergquist D, Hedner U, Pedersen P. The effect of low molecular weight heparin on experimental thrombosis and haemostasis – the influence of production metho. Thromb Res 1987; 45: 739-749
    CrossrefPubMedSearch in Google Scholar
  • 14 Mardiguian J. French Patent No. 2482603 1981
  • 15 Neilsen J, Østergaard P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 1988; 543: 52-56
    PubMedSearch in Google Scholar
  • 16 Cifonelli J, King J. The distribution of 2-acetaminido-2-deoxy-D-glucose residues in mammalian heparins. Carb Res 1972; 21: 173-186
    CrossrefPubMedSearch in Google Scholar
  • 17 Bara L, Billaud B, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
    CrossrefPubMedSearch in Google Scholar
  • 18 Bratt G, Tomebohm E, Lockner D. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-619
    CrossrefPubMedSearch in Google Scholar
  • 19 Matzsch T, Bergqvist D, Hedner U, Øtsergaard P. Effects of an enzymati#cally depolymerised heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 097-101
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Lindahl A, Sandset P, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 03: 439-449
    CrossrefPubMedSearch in Google Scholar
  • 21 Bregengaard C, Nordfang O, Østergaard P, Petersen J, Meyn G, Diness V, Svendsen O, Hedner U. Pharmacokinetics of full length and two domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Lamkjoer A, Østergaard P, Flodgaard H. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb Res 1994; 75: 185-194
    CrossrefPubMedSearch in Google Scholar
  • 23 van RijnJ, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-222
    CrossrefPubMedSearch in Google Scholar
  • 24 Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-935
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Sandset P, Abildgaard U, Larsen M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 801-813
    PubMedSearch in Google Scholar
  • 26 Valentin S, Larnkjor A, Østergaard P, Nielsen J, Nordfang O. Characterisation of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183
    CrossrefPubMedSearch in Google Scholar
  • 27 Wam-Cramer BJ, Maki SL, Rapaport SI. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits. Thromb Haemost 1993; 69: 221-226
    Thieme ConnectPubMedSearch in Google Scholar